First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma.

被引：0
|
作者：
Kaufman, Jonathan [1 ]
Niesvizky, Ruben [2 ]
Stadtmauer, Edward A. [3 ]
Chanan-Khan, Asher [4 ]
Siegel, David [5 ]
Home, Heather [6 ]
Teoh, Nick [6 ]
Leoni, Matthew J. [6 ]
Wegener, William A. [6 ]
Goldenberg, David M. [6 ]
机构：
[1] Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA
[2] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA
[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[4] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[5] Hackensack Univ, Med Ctr, Hackensack, NJ USA
[6] Immunomedics Inc, Morris Plains, NJ USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1266 / 1267
页数：2
相关论文
共 50 条
  • [1] Dose-escalation trial of milatuzumab (humanized anti-CD74 monoclonal antibody) in multiple myeloma
    Kaufman, J. L.
    Niesvizky, R.
    Stadtmauer, E. A.
    Chanan-Khan, A.
    Siegel, D.
    Horne, H.
    Teoh, N.
    Wegener, W. A.
    Goldenberg, D. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Functional Modulation of Dendritic Cells by Milatuzumab, a Humanized Anti-CD74 Monoclonal Antibody
    Chen, Xiaochuan
    Chang, Ken
    Goldenberg, David M.
    JOURNAL OF IMMUNOTHERAPY, 2008, 31 (09) : 955 - 955
  • [3] Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma
    Kaufman, Jonathan L.
    Niesvizky, Ruben
    Stadtmauer, Edward A.
    Chanan-Khan, Asher
    Siegel, David
    Horne, Heather
    Wegener, William A.
    Goldenberg, David M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 163 (04) : 478 - 486
  • [4] Improved therapy of multiple myeloma by combining milatuzumab (Anti-CD74 humanized mAb) and bortezomib: In vitro and in vivo results
    Stein, Rhona
    Goldenberg, David M.
    BLOOD, 2007, 110 (11) : 356A - 357A
  • [5] Efficient Binding, but Moderate Modulation, of Human Dendritic Cell Functions by Milatuzumab, a Humanized Anti-CD74 Monoclonal Antibody
    Chen, Xiaochuan
    Chang, Chien-Hsing
    Goldenberg, David
    BLOOD, 2008, 112 (11) : 916 - 916
  • [6] Milatuzumab (humanized anti-CD74 mAb) targets and kills B-cell malignancies, and blocks signal transduction through CD74
    Stein, Rhona
    Karacay, Habibe
    Sharkey, Robert
    Smith, Mitchell
    Goldenberg, David
    CANCER RESEARCH, 2009, 69
  • [7] A humanized anti-CD70 monoclonal antibody targets CD70-expressing multiple myeloma.
    McEarchern, JA
    McDonagh, C
    Ho, A
    Tai, YT
    Francisco, L
    Klussman, K
    Morris-Tilden, C
    Gordon, K
    Oflazoglu, E
    Kissler, K
    Munshi, N
    Anderson, KC
    Treon, SP
    Carter, P
    Wahl, AF
    Grewal, LS
    Law, CL
    BLOOD, 2005, 106 (11) : 456A - 456A
  • [8] Prevention of Acute Graft-Versus-Host Disease in Human/Mouse Xenogeneic SCID Mouse Model by Humanized Anti-CD74 Monoclonal Antibody, Milatuzumab
    Chen, Xiaochuan
    Chang, Chien-Hsing
    Stein, Rhona
    Cardillo, Thomas M.
    Gold, David V.
    Goldenberg, David M.
    BLOOD, 2012, 120 (21)
  • [9] Phase I trial of a humanized anti-CD40 monoclonal antibody (SGN-40) in the treatment of multiple myeloma.
    Hussein, MA
    Berenson, JR
    Niesvizky, R
    Munshi, NC
    Anderson, KC
    Ryan, KL
    Baumgartner, KT
    Miller, DM
    Drachman, JG
    McDonald, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 580S - 580S
  • [10] Therapeutic effects of the anti-CD74 mAb, milatuzumab, compared to anti-CD20 antibodies, in B-cell lymphomas
    Stein, Rhona
    Goldenberg, David M.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3353S - 3354S
12345